search
Back to results

Carfilzomib and Belatacept for Desensitization (ADAPT)

Primary Purpose

Highly Sensitized Prospective Kidney Transplant Recipients

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
carfilzomib
belatacept
Bone marrow aspiration
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Highly Sensitized Prospective Kidney Transplant Recipients focused on measuring calculated panel reactive antibodies (cPRA), desensitization therapy, human leukocyte antigen (HLA) desensitization

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Individuals who meet all of the following criteria are eligible for enrollment as study subjects-

  1. Subject must be able to understand and provide informed consent
  2. End stage renal disease (ESRD) on dialysis
  3. United Network for Organ Sharing (UNOS) listed for a kidney transplant with any one of the following:

    • Current calculated panel reactive antibodies (cPRA) ≥ 99.9 percent awaiting deceased donor transplant
    • Current cPRA >98 percent (with >5 years of waiting time) awaiting deceased donor transplant
    • Current cPRA >98 percent with Human Leukocyte Antigen (HLA)-incompatible approved living donor and has not received a transplant after 1 year in a kidney paired exchange program
  4. Evidence of established immunity to Epstein-Barr virus (EBV) as demonstrated by serologic testing
  5. Negative result of most recent tuberculosis (TB) testing or appropriately completed latent tuberculosis infection (LTBI) therapy.

    • Testing should be conducted using either a purified protein derivative (PPD) or interferon-gamma release assay (i.e. QuantiFERON-TB, T-SPOT.TB).
    • Negative results from tests performed within 12 months prior to study entry are acceptable in the absence of any intervening exposure to TB.
    • Subjects with a positive test result must have completed appropriate therapy for LTBI.

      • Note: LTBI treatment regimens should be among those endorsed by the Centers for Disease Control and Prevention (CDC), url: https://www.cdc.gov/tb/topic/treatment/ltbi.htm
  6. Negative Food and Drug Administration (FDA)-approved test for human immunodeficiency virus (HIV) diagnosis (at screening or as documented in medical record, up to 12 months prior to screening)
  7. Negative Hepatitis C antibody test at screening or as documented in medical record, up to 12 months prior to screening.

    --If there is a history of treated hepatitis C or there is a suspected false positive hepatitis C virus (HCV) antibody test, then documentation of two consecutive negative HCV quantitative ribonucleic acid (RNA) polymerase chain reaction (PCR) tests separated by at least 6 months is required

  8. Negative result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase- polymerase chain reaction (RT-PCR)
  9. Subjects must have an echocardiogram within the previous 1 year without any of the following findings:

    • severe left ventricular hypertrophy (LVH)
    • greater than mild LVH accompanied by diastolic dysfunction
    • left ventricular ejection fraction <40 percent
    • pulmonary hypertension defined as right ventricular systolic pressure >35 mm Hg or tricuspid regurgitant velocity >2.8 m/s
  10. Female subjects of reproductive potential must have a negative pregnancy test upon study entry
  11. All subjects of reproductive potential must agree to use contraception for the duration of the study
  12. Subjects must have current vaccinations or documented immunity to:

    • varicella (chickenpox)
    • measles
    • hepatitis B
    • pneumococcus
    • influenza, and
    • varicella zoster (if ≥ 50 years old).

      • Note: If subjects require administration of either live or killed vaccines to meet eligibility requirements, they must wait at least 2 weeks between vaccination and the baseline visit (i.e., at least 4 weeks before initiation of therapy)

Living Donor Inclusion Criteria:

Living donors must meet all of the following criteria to be eligible-

  1. Able to understand and provide informed consent for research
  2. Meets United Network for Organ Sharing (UNOS) requirements for kidney organ donation

Exclusion Criteria:

Individuals who meet any of these criteria are not eligible for enrollment as study subjects-

  1. Inability or unwillingness of a subject to give written informed consent or comply with study protocol
  2. Known active current or history of invasive fungal infection, non-tuberculous mycobacterial infection
  3. Hepatitis B surface antigen or core antibody positive
  4. Serious uncontrolled concomitant major organ disease, excluding kidney failure
  5. Chronic respiratory failure
  6. Uncontrolled systemic hypertension
  7. Previous non-kidney solid organ transplant or bone marrow transplant
  8. Any infection requiring hospitalization and intravenous (IV) therapy within 4 weeks of screening or oral therapy within 2 weeks of screening
  9. History of positive result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase reverse transcriptase-polymerase chain reaction (RT-PCR)
  10. Primary or secondary immunodeficiency
  11. History of thromboembolism (except thrombosis of dialysis vascular access site)
  12. Subjects with myocardial infarction within 12 months of screening or cardiac dysrhythmias uncontrolled by medications
  13. History of plasma cell dyscrasia
  14. Known bleeding diathesis or coagulation abnormality
  15. History of active tuberculosis (TB) (even if treated)
  16. Malignancy within the last 5 years except treated basal and squamous cell cancer of the skin or treated cervical cancer in situ
  17. Women who are currently pregnant or nursing
  18. Alcohol, drug, or chemical abuse within 1 year
  19. Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening
  20. Current treatment with other biological drug
  21. Current treatment with any medication which increases the risk of thromboembolic events including oral contraceptives
  22. Currently smoking tobacco
  23. Neutropenia (absolute neutrophil count <1000/microliter) or thrombocytopenia (platelet count <100,000/microliter) within 4 weeks prior to screening
  24. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times upper limit of normal (ULN) or total bilirubin ≥ 2 times ULN
  25. Past or current medical problems or findings from physical examination or laboratory testing not listed above, which, in the opinion of the investigator, may:

    • pose additional risks from participation in the study
    • interfere with the subject's ability to comply with study requirements, or
    • impact the quality or interpretation of the data obtained from the study.

Exclusion Criteria for Living Donors:

1. There are no exclusion criteria for living donors.

Sites / Locations

  • Duke Transplant Center, Duke University Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1 (N=5 Subjects)

Cohort 2 (N=10 Subjects)

Arm Description

The two investigational agents used in this study are carfilzomib and belatacept. Per protocol, Carfilzomib administered intravenously: Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43). Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99). Per protocol, Belatacept: -Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert.

The enrollment of ten additional subjects and dosing regimen is dependent on the results in Cohort 1.° Per protocol, Carfilzomib administered intravenously: Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43). Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99). Per protocol, Belatacept: -Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert. ° May be modified based on the safety and efficacy analysis of Cohort 1.

Outcomes

Primary Outcome Measures

Proportion of subjects who do not meet a stopping rule for safety and remain free of all of the safety events listed in the outcome description, through Week 20 post treatment initiation or until receiving a transplant, whichever occurs earlier
Proportion of subjects who have not met a subject stopping rule, and remain free of all of the following through Week 20 post treatment initiation or until receiving a transplant, whichever occurs earlier: Grade 3 or higher infusion reaction, Grade 3 or higher infections, and Any malignancy. The study site will grade the severity of adverse events experienced by the study subjects according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Published November 27, 2017).
Proportion of subjects who meet any one of the pre-specified events detailed in the outcome description: from Baseline to Week 20 post treatment initiation
Proportion of subjects who meet any one of the following compared to Baseline (Visit 0): Elimination of one human leukocyte antigen (HLA) antibody at Week 20 (which is Study Week 24) post treatment initiation, 50% or greater reduction in the mean fluorescence intensity (MFI) of at least three HLA antibodies at Week 20 (which is Study Week 24) after starting treatment, and/or Kidney transplant with a previously incompatible donor within 20 weeks after starting treatment without graft loss due to acute antibody mediated rejection occurring within the first four weeks post-transplant and caused by an anamnestic response.

Secondary Outcome Measures

Proportion of subjects transplanted with a previously incompatible donor within 52 weeks after starting treatment
Clinical outcome measure. Subjects may receive a kidney transplant while in the study, either from a living or deceased donor to whom they were previously compatible, or from a previously incompatible donor in case there is a significant reduction in HLA antibody.
Proportion of subjects with biopsy-proven acute or chronic antibody mediated rejection (AMR) within 52 weeks post-transplant in subjects who undergo a kidney transplant
Clinical outcome measure. Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Number of biopsy-proven acute or chronic AMR events within 52 weeks post-transplant in subjects who undergo a kidney transplant
Clinical outcome measure. Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 20 weeks after starting treatment
A measure of infection-related morbidity.
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 52 weeks after starting treatment
A measure of infection-related morbidity.
Incidence of cytomegalovirus (CMV) infection within 20 weeks after starting treatment
CMV infection confirmed by the presence of detectable CMV in blood by polymerase chain reaction [PCR] diagnostic testing, regardless of whether signs or symptoms are present.
Incidence of cytomegalovirus (CMV) infection within 52 weeks after starting treatment
CMV infection confirmed by the presence of detectable CMV in blood by polymerase chain reaction [PCR] diagnostic testing, regardless of whether signs or symptoms are present.
Incidence of cytomegalovirus (CMV) disease within 20 weeks after starting treatment
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Incidence of cytomegalovirus (CMV) disease within 52 weeks after starting treatment
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Incidence of post-transplant lymphoproliferative disorder (PTLD)
As per diagnosis by local pathologist and treating physician.
Mean number of Human Leukocyte Antigen (HLA) antibodies eliminated, compared to Baseline
Mechanistic outcome measure focusing on change in donor specific antibodies (DSA).
Mean proportion of Human Leukocyte Antigen (HLA) antibodies eliminated, compared to Baseline
Mechanistic outcome measure focusing on change in donor specific antibodies (DSA).
Mean percent reduction from Baseline in mean fluorescence intensity (MFI) of the immunodominant Human Leukocyte Antigen (HLA) antibody, Class I and Class II
Mechanistic outcome measure focusing on change in donor specific antibodies (DSA).
Mean percent reduction from Baseline in mean fluorescence intensity (MFI) of Human Leukocyte Antigen (HLA) antibodies classified by an MFI >10,000 at treatment initiation
Mechanistic outcome measure focusing on change in donor specific antibodies. An MFI of >10,000 reflects a strong DSA intensity. (Reference: A measure of 0 reflects no donor specific antibodies).

Full Information

First Posted
August 17, 2021
Last Updated
February 8, 2023
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05017545
Brief Title
Carfilzomib and Belatacept for Desensitization
Acronym
ADAPT
Official Title
Measuring the Impact of Carfilzomib and Belatacept on Allogeneic Desensitization in Prospective Kidney Transplant Recipients (ITN089ST)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 28, 2021 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
April 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Immune Tolerance Network (ITN), Bristol-Myers Squibb, PPD, Rho Federal Systems Division, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for them or, they never receive a compatible donor, and die while on the kidney transplant waitlist. The purpose of this study is to find out whether two drugs, carfilzomib (Kyprolis®),and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney donor for them.
Detailed Description
This study will enroll 15 eligible participants, 18 to 65 years of age, with end stage renal failure on dialysis who are on the waiting list for a deceased donor transplant with calculated panel reactive antibodies (cPRA) ≥99.9% or >98% (with >5 years of waiting time) or, those with cPRA >98% and an human leukocyte antigen (HLA)-incompatible approved living donor who have not received a transplant after 1 year in a paired kidney exchange program. The study will evaluate whether the study treatment is safe and can lower the participant's immune system's sensitization to kidney donors, making it easier to find a well-matched kidney for them. Participants in the study will be enrolled in two consecutive Cohorts of 5 and 10 patients respectively. The total duration of participation in the study will be 76 weeks for Cohort 1 and 68 weeks for Cohort 2. Participants who undergo kidney transplantation while enrolled in the study will undergo an additional 52 weeks of follow up post-transplant. The duration of participation for living donors is one study visit. Their participation in the study ends upon completion of this study visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Highly Sensitized Prospective Kidney Transplant Recipients
Keywords
calculated panel reactive antibodies (cPRA), desensitization therapy, human leukocyte antigen (HLA) desensitization

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1 (N=5 Subjects)
Arm Type
Experimental
Arm Description
The two investigational agents used in this study are carfilzomib and belatacept. Per protocol, Carfilzomib administered intravenously: Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43). Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99). Per protocol, Belatacept: -Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert.
Arm Title
Cohort 2 (N=10 Subjects)
Arm Type
Experimental
Arm Description
The enrollment of ten additional subjects and dosing regimen is dependent on the results in Cohort 1.° Per protocol, Carfilzomib administered intravenously: Cycle 1 will consist of 2 doses in week 4 (Day 28 and 29). If tolerated, the dose will be increased and administered twice a week in weeks 5 (Day 35 and 36) and 6 (Day 42 and 43). Cycle 2 will consist of a total of 6 doses, administered twice weekly in weeks 12 (Day 84 and 85), 13 (Day 91 and 92) and 14 (Day 98 and 99). Per protocol, Belatacept: -Belatacept will be administered intravenously on days 29 (week 4), 33 (week 5), and weeks 6, 8, 12, 16, then at a lower dose at week 20, 24, 28, 32, 36, 40, 44, 48, 52, and 56. Dosing is based on the recommended dose in the package insert. ° May be modified based on the safety and efficacy analysis of Cohort 1.
Intervention Type
Biological
Intervention Name(s)
carfilzomib
Other Intervention Name(s)
Kyprolis®
Intervention Description
Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert. Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant.
Intervention Type
Biological
Intervention Name(s)
belatacept
Other Intervention Name(s)
Nulojix®
Intervention Description
Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
Intervention Type
Procedure
Intervention Name(s)
Bone marrow aspiration
Intervention Description
Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been >4 weeks since the previous bone marrow aspiration.
Primary Outcome Measure Information:
Title
Proportion of subjects who do not meet a stopping rule for safety and remain free of all of the safety events listed in the outcome description, through Week 20 post treatment initiation or until receiving a transplant, whichever occurs earlier
Description
Proportion of subjects who have not met a subject stopping rule, and remain free of all of the following through Week 20 post treatment initiation or until receiving a transplant, whichever occurs earlier: Grade 3 or higher infusion reaction, Grade 3 or higher infections, and Any malignancy. The study site will grade the severity of adverse events experienced by the study subjects according to the criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Published November 27, 2017).
Time Frame
Up to 20 weeks post treatment initiation
Title
Proportion of subjects who meet any one of the pre-specified events detailed in the outcome description: from Baseline to Week 20 post treatment initiation
Description
Proportion of subjects who meet any one of the following compared to Baseline (Visit 0): Elimination of one human leukocyte antigen (HLA) antibody at Week 20 (which is Study Week 24) post treatment initiation, 50% or greater reduction in the mean fluorescence intensity (MFI) of at least three HLA antibodies at Week 20 (which is Study Week 24) after starting treatment, and/or Kidney transplant with a previously incompatible donor within 20 weeks after starting treatment without graft loss due to acute antibody mediated rejection occurring within the first four weeks post-transplant and caused by an anamnestic response.
Time Frame
Baseline (Visit 0) to Week 20 post treatment initiation
Secondary Outcome Measure Information:
Title
Proportion of subjects transplanted with a previously incompatible donor within 52 weeks after starting treatment
Description
Clinical outcome measure. Subjects may receive a kidney transplant while in the study, either from a living or deceased donor to whom they were previously compatible, or from a previously incompatible donor in case there is a significant reduction in HLA antibody.
Time Frame
Within 52 weeks post treatment initiation
Title
Proportion of subjects with biopsy-proven acute or chronic antibody mediated rejection (AMR) within 52 weeks post-transplant in subjects who undergo a kidney transplant
Description
Clinical outcome measure. Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Time Frame
Within 52 weeks post-transplant
Title
Number of biopsy-proven acute or chronic AMR events within 52 weeks post-transplant in subjects who undergo a kidney transplant
Description
Clinical outcome measure. Antibody mediated rejection (AMR) is an important cause of graft loss after organ transplantation and is caused by anti-donor-specific antibodies, especially anti- human leukocyte antigen (HLA) antibodies.
Time Frame
Within 52 weeks post-transplant
Title
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 20 weeks after starting treatment
Description
A measure of infection-related morbidity.
Time Frame
Within 20 weeks post treatment initiation
Title
Incidence of invasive fungal infections, mycobacterial infections or Pneumocystis jirovecii infection within 52 weeks after starting treatment
Description
A measure of infection-related morbidity.
Time Frame
Within 52 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) infection within 20 weeks after starting treatment
Description
CMV infection confirmed by the presence of detectable CMV in blood by polymerase chain reaction [PCR] diagnostic testing, regardless of whether signs or symptoms are present.
Time Frame
Within 20 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) infection within 52 weeks after starting treatment
Description
CMV infection confirmed by the presence of detectable CMV in blood by polymerase chain reaction [PCR] diagnostic testing, regardless of whether signs or symptoms are present.
Time Frame
Within 52 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) disease within 20 weeks after starting treatment
Description
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Time Frame
Within 20 weeks post treatment initiation
Title
Incidence of cytomegalovirus (CMV) disease within 52 weeks after starting treatment
Description
CMV disease defined by the presence of detectable CMV in the blood and the presence of other clinical manifestations attributable to the CMV virus.
Time Frame
Within 52 weeks post treatment initiation
Title
Incidence of post-transplant lymphoproliferative disorder (PTLD)
Description
As per diagnosis by local pathologist and treating physician.
Time Frame
Within 52 weeks post-transplant
Title
Mean number of Human Leukocyte Antigen (HLA) antibodies eliminated, compared to Baseline
Description
Mechanistic outcome measure focusing on change in donor specific antibodies (DSA).
Time Frame
Baseline (Visit 0), Weeks 16, 20, and 52 post treatment initiation
Title
Mean proportion of Human Leukocyte Antigen (HLA) antibodies eliminated, compared to Baseline
Description
Mechanistic outcome measure focusing on change in donor specific antibodies (DSA).
Time Frame
Baseline (Visit 0), Weeks 16, 20, and 52 post treatment initiation
Title
Mean percent reduction from Baseline in mean fluorescence intensity (MFI) of the immunodominant Human Leukocyte Antigen (HLA) antibody, Class I and Class II
Description
Mechanistic outcome measure focusing on change in donor specific antibodies (DSA).
Time Frame
Baseline (Visit 0), Weeks 16, 20, and 52 post treatment initiation
Title
Mean percent reduction from Baseline in mean fluorescence intensity (MFI) of Human Leukocyte Antigen (HLA) antibodies classified by an MFI >10,000 at treatment initiation
Description
Mechanistic outcome measure focusing on change in donor specific antibodies. An MFI of >10,000 reflects a strong DSA intensity. (Reference: A measure of 0 reflects no donor specific antibodies).
Time Frame
Baseline (Visit 0), Weeks 16, 20, and 52 post treatment initiation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individuals who meet all of the following criteria are eligible for enrollment as study subjects- Subject must be able to understand and provide informed consent End stage renal disease (ESRD) on dialysis United Network for Organ Sharing (UNOS) listed for a kidney transplant with any one of the following: Current calculated panel reactive antibodies (cPRA) ≥ 99.9 percent awaiting deceased donor transplant Current cPRA >98 percent (with >5 years of waiting time) awaiting deceased donor transplant Current cPRA >98 percent with Human Leukocyte Antigen (HLA)-incompatible approved living donor and has not received a transplant after 1 year in a kidney paired exchange program Evidence of established immunity to Epstein-Barr virus (EBV) as demonstrated by serologic testing Negative result of most recent tuberculosis (TB) testing or appropriately completed latent tuberculosis infection (LTBI) therapy. Testing should be conducted using either a purified protein derivative (PPD) or interferon-gamma release assay (i.e. QuantiFERON-TB, T-SPOT.TB). Negative results from tests performed within 12 months prior to study entry are acceptable in the absence of any intervening exposure to TB. Subjects with a positive test result must have completed appropriate therapy for LTBI. Note: LTBI treatment regimens should be among those endorsed by the Centers for Disease Control and Prevention (CDC), url: https://www.cdc.gov/tb/topic/treatment/ltbi.htm Negative Food and Drug Administration (FDA)-approved test for human immunodeficiency virus (HIV) diagnosis (at screening or as documented in medical record, up to 12 months prior to screening) Negative Hepatitis C antibody test at screening or as documented in medical record, up to 12 months prior to screening. --If there is a history of treated hepatitis C or there is a suspected false positive hepatitis C virus (HCV) antibody test, then documentation of two consecutive negative HCV quantitative ribonucleic acid (RNA) polymerase chain reaction (PCR) tests separated by at least 6 months is required Negative result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase- polymerase chain reaction (RT-PCR) Subjects must have an echocardiogram within the previous 1 year without any of the following findings: severe left ventricular hypertrophy (LVH) greater than mild LVH accompanied by diastolic dysfunction left ventricular ejection fraction <40 percent pulmonary hypertension defined as right ventricular systolic pressure >35 mm Hg or tricuspid regurgitant velocity >2.8 m/s Female subjects of reproductive potential must have a negative pregnancy test upon study entry All subjects of reproductive potential must agree to use contraception for the duration of the study Subjects must have current vaccinations or documented immunity to: varicella (chickenpox) measles hepatitis B pneumococcus influenza, and varicella zoster (if ≥ 50 years old). Note: If subjects require administration of either live or killed vaccines to meet eligibility requirements, they must wait at least 2 weeks between vaccination and the baseline visit (i.e., at least 4 weeks before initiation of therapy) Living Donor Inclusion Criteria: Living donors must meet all of the following criteria to be eligible- Able to understand and provide informed consent for research Meets United Network for Organ Sharing (UNOS) requirements for kidney organ donation Exclusion Criteria: Individuals who meet any of these criteria are not eligible for enrollment as study subjects- Inability or unwillingness of a subject to give written informed consent or comply with study protocol Known active current or history of invasive fungal infection, non-tuberculous mycobacterial infection Hepatitis B surface antigen or core antibody positive Serious uncontrolled concomitant major organ disease, excluding kidney failure Chronic respiratory failure Uncontrolled systemic hypertension Previous non-kidney solid organ transplant or bone marrow transplant Any infection requiring hospitalization and intravenous (IV) therapy within 4 weeks of screening or oral therapy within 2 weeks of screening History of positive result for 2019-novel Coronavirus (2019-nCoV) by real-time reverse transcriptase reverse transcriptase-polymerase chain reaction (RT-PCR) Primary or secondary immunodeficiency History of thromboembolism (except thrombosis of dialysis vascular access site) Subjects with myocardial infarction within 12 months of screening or cardiac dysrhythmias uncontrolled by medications History of plasma cell dyscrasia Known bleeding diathesis or coagulation abnormality History of active tuberculosis (TB) (even if treated) Malignancy within the last 5 years except treated basal and squamous cell cancer of the skin or treated cervical cancer in situ Women who are currently pregnant or nursing Alcohol, drug, or chemical abuse within 1 year Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational drug, whichever is longer) of screening Current treatment with other biological drug Current treatment with any medication which increases the risk of thromboembolic events including oral contraceptives Currently smoking tobacco Neutropenia (absolute neutrophil count <1000/microliter) or thrombocytopenia (platelet count <100,000/microliter) within 4 weeks prior to screening Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times upper limit of normal (ULN) or total bilirubin ≥ 2 times ULN Past or current medical problems or findings from physical examination or laboratory testing not listed above, which, in the opinion of the investigator, may: pose additional risks from participation in the study interfere with the subject's ability to comply with study requirements, or impact the quality or interpretation of the data obtained from the study. Exclusion Criteria for Living Donors: 1. There are no exclusion criteria for living donors.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stuart J. Knechtle, MD
Organizational Affiliation
Duke Department of Surgery, Duke University School of Medicine
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Annette M. Jackson, PhD
Organizational Affiliation
Duke Department of Surgery, Duke University School of Medicine
Official's Role
Study Chair
Facility Information:
Facility Name
Duke Transplant Center, Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kitza Williams, MSN, FNP
Phone
919-681-1035
Email
kitza.williams@duke.edu
First Name & Middle Initial & Last Name & Degree
Stuart J. Knechtle, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD Sharing Time Frame
On average, within 24 months after database lock for the trial.
IPD Sharing Access Criteria
Open access.
IPD Sharing URL
https://www.immport.org/home
Links:
URL
https://www.immunetolerance.org/
Description
Immune Tolerance Network
URL
https://www.niaid.nih.gov/
Description
National Institute of Allergy and Infectious Diseases
URL
https://www.niaid.nih.gov/about/dait
Description
Division of Allergy, Immunology, and Transplantation

Learn more about this trial

Carfilzomib and Belatacept for Desensitization

We'll reach out to this number within 24 hrs